

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

The effect of ondansetron on reduction of etomidate-induced myoclonic movements in patients with ophthalmic surgery

Protocol summary

Study aim

The effect of ondansetron on myoclonic reduction induced by Etomidate

Design

Clinical trial with control group, with parallel groups, randomized, phase 3 on 60 patients. The block method is used for randomization.

Settings and conduct

The study included 60 adult patients (over 18 years old) who are candidates for elective ophthalmic surgery with ASA I-II who are under general anesthesia for elective ophthalmic surgery in Mshhad Khatam Hospital. Patients entered the study after obtaining informed consent and explaining the study. Sampling method is available sampling method. Patients are treated with 5cc/kg fluid for 10minutes before induction and routine monitoring includes pulse Oximetry, ECG, NIBP and capnography are performed for patients. Patients with random allocation (block method) in 2 groups receiving ondansetron (4mg (IV) (group O) or control group with 5cc of N/S (IV) before They receive from Etomidate, are placed and receive this drug as a prodrug 180 seconds before induction with Etomidate at the rate of 0.3 mg/kg. The incidence of myoclonus is assessed by resident of anesthesia who is not aware of the groups, (triple blind) and the severity of myoclonus with a score between 0 and 3 are measured.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Adults (over 18 years old) ASAII-I who are candidates for elective ophthalmic surgery. And consent to participate in the study. Exclusion criteria: Patients with adrenal dysfunction Drug allergy Mental disorders Neuromuscular disease Seizures Electrolyte disorders Surgery with a high risk of nausea and vomiting such as strabismus

Intervention groups

Patients with randomized allocation (block method) are divided into 2 groups receiving ondansetron (4 mg (IV) (group O) or the control group receiving 5cc of normal saline (IV) before Etomidate

Main outcome variables

Incidence and Intensity of myoclonic movements

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20190510043545N2**

Registration date: **2021-10-02, 1400/07/10**

Registration timing: **prospective**

Last update: **2021-10-02, 1400/07/10**

Update count: **0**

Registration date

2021-10-02, 1400/07/10

Registrant information

Name

seyed javad purafzali firuzabadi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 51 3728 2267

Email address

sjvdpurafzali@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-10-07, 1400/07/15

Expected recruitment end date

2021-11-06, 1400/08/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of ondansetron on reduction of etomidate-induced myoclonic movements in patients with ophthalmic surgery

Public title

The effect of ondansetron on reduction of etomidate-induced myoclonic movements

Purpose

Prevention

Inclusion/Exclusion criteria**Inclusion criteria:**

Adults (over 18 years old) ASAII-III who are candidates for elective ophthalmic surgery. And consent to participate in the study.

Exclusion criteria:

Patients with adrenal dysfunction Drug allergy Mental disorders Neuromuscular disease Seizures Electrolyte disorders Surgery with a high risk of nausea and vomiting such as strabismus

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Outcome assessor
- Data analyser

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Participants will be randomly divided into two groups using a random blocking method with a size of 4 blocks using Software Allocation Random (RAS) software with a 1: 1 allocation ratio by the non-involved person in the study. To conceal the allocation, closed opaque envelopes will be prepared and numbered according to the number of samples. Envelope preparation and random allocation sequencing will be performed by the non-research person.

Blinding (investigator's opinion)

Triple blinded

Blinding description

Participants are divided into two groups receiving normal saline (control group) and ondansetron (intervention group) as prodrug. The participant is injected intravenously and does not know which group he is in. The person assigning the samples to the groups does not know the assigned group. The person examining the incidence and severity of myoclonus is not aware of the participant's assigned group, and the analyzer is not aware of the assigned group.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Mashhad University of Medical Sciences

Street address

Knowledge and Health City - In the end of Shahid Fakouri Blvd (In front of Fakouri 94) - Mashhad - Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

91778-99191

Approval date

2021-06-15, 1400/03/25

Ethics committee reference number

IR.MUMS.MEDICAL.REC.1400.234

Health conditions studied**1****Description of health condition studied**

etomidate-induced myoclonic movements

ICD-10 code

G25.3

ICD-10 code description

Myoclonus

Primary outcomes**1****Description**

Intensity of myoclonus

Timepoint

The occurrence and severity of myoclonus are controlled from the time of injection to 90 seconds after atomiditis injection.

Method of measurement

myoclonic movements score

Secondary outcomes

empty

Intervention groups

1

Description

The ondansetron group received 4 mg (IV) (group O) before Etomidate and received the drug as a prodrug 180 seconds before induction with Etomidate at a dose of 0.3 mg / kg. This drug is used as a single dose of 4 mg intravenously 180 seconds before Etomidate injection. Ondansetron is a serotonin antagonist. In all participants, the drug will be used by one company.

Category

Prevention

2

Description

Control group: The control group received 5 cc of normal saline (IV) before Etomidate and received the drug as a prodrug 180 seconds before induction with Etomidate at the rate of 0.3 mg / kg. Normal saline will be injected as a placebo.

Category

Prevention

Recruitment centers

1

Recruitment center

Name of recruitment center

Khatam hospital

Full name of responsible person

Mohamad Alipour

Street address

Mashhad - Abu Talib crossroads to Ferdowsi Square -
Shahid Gharani St. 41

City

Mashhad

Province

Razavi Khorasan

Postal code

91959659919

Phone

+98 51 3728 1401

Email

sjvdpurafzali@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Mohsen Tafghodi Piade Gheibi

Street address

Knowledge and Health City - In the end of Shahid
Fakouri Blvd (In front of Fakouri 94) - Mashhad - Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

91778-99191

Phone

+98 51 3841 2081

Email

Info.en@mums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Mashhad University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Mohamad Alipour

Position

Associate professor of anesthesiology

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Ahmad Abad Blvd , Mashhad , Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

9176699199

Phone

+98 51 3840 0000

Email

sjvdpurafzali@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Mashhad University of Medical Sciences

Full name of responsible person

Mohamad Alipour

Position

Associate professor of anesthesiology

Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Ahmad Abad Blvd , Mashhad , Iran
City
Mashhad
Province
Razavi Khorasan
Postal code
9176699199
Phone
+98 51 3840 0000
Email
sjvdpurafzali@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Mohamad Alipour
Position
Associate professor of anesthesiology
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Ahmad Abad Blvd , Mashhad , Iran
City

Mashhad
Province
Razavi Khorasan
Postal code
9176699199
Phone
+98 51 3840 0000
Email
sjvdpurafzali@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available